Proteinase-Activated Receptor 2: Differential Activation of the Receptor by Tethered Ligand and Soluble Peptide Analogs

  1. Bahjat Al-Ani1,
  2. Suranga J. Wijesuriya1 and
  3. Morley D. Hollenberg1,2
  1. 1Diabetes and Endocrine Research Group, Departments of Pharmacology and Therapeutics (B.A.-A., S.J.W., M.D.H.) and 2Medicine (M.D.H.), University of Calgary, Faculty of Medicine, Calgary, Alberta, Canada
  1. Dr. Bahjat Al-Ani, Department of Pharmacology and Therapeutics, Health Sciences Centre University of Calgary, 3330 Hospital Dr. NW., Calgary AB, Canada T2N 4N1. E-mail:alani{at}ucalgary.ca

Abstract

Activation of rat proteinase-activated receptor 2 (PAR2) by trypsin involves the unmasking of the tethered sequence S37LIGRL42 that either tethered or on its own as a free peptide, activates PAR2. We aimed to determine whether different peptide sequences acting either as trypsin-revealed tethered ligands or as soluble peptides had the same relative activities for triggering the receptor. A comparison was also made between the different soluble and tethered receptor activating sequences in receptor constructs with extracellular loop 2 (ECL2) residues E232E233 (PAR2SR/EE) mutated to R232R233 (PAR2SR/RR). Using site-directed mutagenesis, we prepared PAR2 constructs with trypsin-revealed tethered ligand sequences corresponding to the synthetic receptor-activating peptides (PAR2APs): SLIGRL-NH2 (SR-NH2), SLIGAL-NH2 (SA-NH2), and SLIGEL-NH2(SE-NH2). Kirsten virus-transformed rat kidney cells stably expressing 1) wild-type PAR2 with site-mutated tethered ligands (PAR2SA/EE and PAR2SE/EE); 2) wild-type PAR2 with ECL2 mutated to R232R233 (PAR2SR/RR); and 3) PAR2 constructs with both the RR mutation in ECL2 and a mutation in the tethered ligand (PAR2SA/RR and PAR2SE/RR) were assessed for receptor-mediated calcium signaling and cell growth inhibition, upon activation either by trypsin or the above-mentioned PAR2APs. Trypsin exerted equivalent and full agonist activity on the PAR2 constructs, causing a maximum response between 20 to 80 nM. In contrast, the PAR2APs as free peptide agonists showed marked potency differences in all wild-type receptors with mutated tethered ligands (SR-NH2 ≫ SA-NH2 ≫ SE-NH2) and in all ECL2 RR mutated constructs (SE-NH2 > SR-NH2 ≫ SA-NH2). We conclude that for receptor activation, the trypsin-revealed PAR2 tethered ligand sequence interacts differently for receptor activation than does the same peptide sequence as a free peptide.

Footnotes

  • 1 Amino acids are abbreviated by their one-letter code.

  • These studies were supported in large part by a Term Grant from the Canadian Institutes of Health Research (formerly Medical Research Council of Canada) and by ancillary support from a Kidney Foundation of Canada operating grant and a Health Research Foundation Rx and D Graduate Studentship (to S.J.W.).

  • Abbreviations:
    PAR
    proteinase-activated receptor
    AP
    activating peptide
    ECL2
    extracellular loop 2
    SAR
    structure-activity relationship
    PCR
    polymerase chain reaction
    KNRK
    Kirsten virus-transformed rat kidney
    FACS
    fluorescence-activated cell sorting
    B5
    antibody targeted to the cleavage/activation sequence (GPNSKGRSLIGRLDTP) of rat PAR2
    DMEM
    Dulbecco's modified Eagle's medium
    REC
    relative effective concentration
    • Received December 14, 2001.
    • Accepted February 7, 2002.
« Previous | Next Article »Table of Contents